Technical analysis of Jupiter Neurosciences, Inc. (JUNS): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues.
Price Performance
| 1 month | -42.09% |
| 3 months | -83.59% |
| Year-to-date | -96.17% |
| 1 year | -97.38% |
52-Week Range
| 52-week High | $138.00 |
| 52-week Low | $2.88 |
| Avg Volume (90d) | 745K |
Technical Indicators
| SMA 50 | $7.09 |
| SMA 200 | $33.28 |
| Beta | 2.78 |
| 30-day Volatility (annualised) | 164.9% |
| Price vs SMA 50 | -58.6% |
| Price vs SMA 200 | -91.2% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $107.25 | |
| 2025-11 | $92.25 | -14.0% |
| 2025-12 | $76.50 | -17.1% |
| 2026-01 | $39.59 | -48.2% |
| 2026-02 | $39.75 | +0.4% |
| 2026-03 | $28.22 | -29.0% |
| 2026-04 | $28.44 | +0.8% |
| 2026-05 | $19.20 | -32.5% |
| 2026-06 | $16.07 | -16.3% |
| 2026-07 | $6.75 | -58.0% |
| 2026-08 | $3.54 | -47.6% |
| 2026-09 | $2.93 | -17.2% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | $144M |
| 2026-09-14 | | $898M |
Price
| Price | $2.93 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -4.27 |
| EV / EBITDA | -0.19 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | -4.78 |
| Current Ratio | 0.66 |